Oncotarget [JOURNAL]

Sun 200 papers

RSS

Retraction: Role of high expression levels of STK39 in the growth migration and invasion of nonsmall cell type lung cancer cells.

Li Z, Zhu W, Xiong L … +3 more , Yu X, Chen X, Lin Q

Oncotarget · 2026 Jan · PMID 42127246 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Artificial intelligence in nutritional oncology: From isolated screening tools to agentic intervention systems.

Sarkar A, Singh-Wolkenhauer Y

Oncotarget · 2026 Jan · PMID 42080704 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.

Speyer CB, Klingbeil KD, Nakasaki M … +5 more , Dry SM, Singh AS, Arzoo KK, Eilber FC, Crompton JG

Oncotarget · 2026 May · PMID 42080642 · Full text

Copyright: © 2026 Speyer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in a... Copyright: © 2026 Speyer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Gastrointestinal stromal tumors (GISTs) are molecularly defined by oncogenic alterations that predict clinical behavior and response to therapy. Activating mutations in KIT or PDGFRA characterize most GISTs and confer sensitivity to imatinib, whereas succinate dehydrogenase (SDH)–deficient GISTs lack these mutations and are typically imatinib resistant. These molecular subtypes are generally considered mutually exclusive. We report a rare case of a small bowel GIST harboring both a somatic KIT exon 9 A502_Y503 duplication and a germline inactivating SDHC mutation (p.R50C). The patient received neoadjuvant high-dose imatinib with a marked radiographic and metabolic response, followed by complete surgical resection. Pathology demonstrated spindle cell GIST with significant treatment effect and retained SDHB expression. This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.

Free PDF PubMed ↗

Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023.

Kahlon N, Bansal N, Baddam S … +2 more , Rajput J, Qureshi Z

Oncotarget · 2026 Apr · PMID 42047296 · Full text

Copyright: © 2026 Kahlon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in a... Copyright: © 2026 Kahlon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Multiple myeloma (MM), the second most common hematologic malignancy in the United States, has undergone transformative therapeutic innovation over the past five decades. Using SEER data from 1975 to 2023, we conducted a retrospective cross-sectional analysis to evaluate MM-specific mortality trends in relation to major treatment milestones. Age-adjusted mortality rates and Annual Percent Change (APC) were estimated using Joinpoint regression. Mortality increased from 1975 to 1994 (APC: 1.43%; P < .01), declined modestly from 1994 to 2002 (–0.70%; P = .02), dropped steeply from 2002 to 2009 (–1.85%; P < .01), plateaued between 2009 and 2014 (0.52%; P = .10), resumed decline from 2014 to 2021 (–1.73%; P < .01), and sharply decreased from 2021 to 2023 (–5.64%; P < .01). These inflection points align with the introduction of stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and next-generation immunotherapies including CAR T-cell therapy and bispecific antibodies. While these advances have improved survival, they also introduced chronic treatment burdens and rising costs. Our findings highlight the real-world impact of targeted therapies on population-level outcomes and underscore the urgent need for care models that ensure accessibility, affordability, and long-term sustainability in the era of precision oncology.

Free PDF PubMed ↗

Correction: Aloeemodin as drug candidate for cancer therapy.

xD Zenver N, Saeed M, Demirezer LXTXM … +1 more , Efferth T

Oncotarget · 2026 Jan · PMID 42031515 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Correction: A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.

Pramanik D, Campbell NR, Das S … +10 more , Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C, Steenbergen C, Gabrielson KL, Maitra A, Maitra A

Oncotarget · 2026 Jan · PMID 42031475 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗